| | | | |
CUSIP NO. 02083G100 | | 13G | | Page 8 of 11 Pages |
Introductory Note: This statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock (“Common Stock”), of Alpine Immune Science, Inc. (the “Issuer”).
Alpine Immune Science, Inc. (the “Issuer”)
Item 1(b) | Address of Issuer’s principal executive offices: |
Alpine Immune Science, Inc.
201 Elliott Avenue West, Suite 230
Seattle, WA 98119
Items 2(a) | Name of Reporting Persons filing: |
Omega Fund VI, L.P. (“Omega Fund”)
Omega Fund VI GP, L.P. (“Omega GP”)
Omega Fund VI GP Manager, Ltd. (“Omega Ltd.”)
Claudio Nessi (“Nessi”)
Otello Stampacchia (“Stampacchia”)
Anne-Mari Paster (“Paster”)
Item 2(b) | Address or principal business office or, if none, residence: |
The address of the principal business office of Omega Fund, Omega GP, Omega Ltd, Nessi, Stampacchia, and Paster, is c/o Omega Fund Management, LLC, 888 Boylston Street, Suite 1111, Boston, MA 02199.
| | |
Name | | Citizenship or Place of Organization |
Omega Fund | | Cayman Islands |
Omega GP | | Cayman Islands |
Omega Ltd. | | Cayman Islands |
Nessi | | Switzerland |
Stampacchia | | Italy |
Paster | | United States of America |
Item 2(d) | Title of class of securities: |
Common Stock
02083G100
Item 3 | If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a: |
Not applicable.
The following information with respect to the ownership of Common Stock of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of July 28, 2020.